← Back to Investors

OMX Ventures

OMX Ventures is an early-stage life sciences venture firm focused on transformative companies in healthcare and biotechnology. They specialize in seed and Series A investments, backing founders applying technology and scientific innovation to improve human health.

Location
San Francisco, California, USA
Founded
2015
AUM
$200M+
Investment Range
$500K - $10M
Portfolio Companies
23
Focus
biotech-focused
Fund Stages
seed, series-a

Investment Thesis

OMX Ventures invests in early-stage life sciences companies with breakthrough potential. They focus on the intersection of technology and biology, backing founders who are leveraging computational biology, AI/ML, genomics, and novel platforms to create the next generation of healthcare companies.

Team

Partners / Managing Directors (Health & Bio Focus)

  • Investment team - Life sciences and technology specialists

Focus Areas

  • Computational biology
  • Genomics
  • AI/ML in healthcare
  • Drug discovery
  • Diagnostics
  • Digital health
  • Platform technologies

Notable Investments

  • Early-stage life sciences companies
  • High fit for genomics landscape

Sources

Portfolio Companies

NameLocationFoundedCategories
Epana Biosciences--
autoimmuneai+4
Mythic TherapeuticsWaltham, Massachusetts, USA2020
antibody-therapytherapeutics+3
COMPASS PathwaysLondon, United Kingdom2016
therapeuticspsychiatry+4
Delix TherapeuticsBoston, Massachusetts, USA2019
therapeuticspsychiatry+3
Finch TherapeuticsSomerville, Massachusetts, USA2013
microbiometherapeutics+3
ReplaySan Diego, California, USA2021
gene-therapycell-therapy+3
ReAx Therapeutics--
biotechchemoproteomics+2
Tera TherapeuticsBoston, Massachusetts, USA2021
gene-therapygene-editing+3
Type6 TherapeuticsBoston, Massachusetts, USA2021
oncologytherapeutics+3
Syndex BioSan Francisco, California, USA2022
genomicsdrug-discovery+3
VedaBioNew Haven, Connecticut, USA2021
molecular-diagnosticsdiagnostics+2
MatterworksSan Francisco, California, USA2020
aimachine-learning+3
CellsonicsNetherlands2021
single-celltissue-dissociation+3
Glyphic BiotechnologiesBoston, Massachusetts, USA2019
proteomicsbiotech+2
Constructive BioCambridge, United Kingdom2021
synthetic-biologysynthetic-genomes+3
Aperiam BioSeattle, Washington, USA2020
biotechprotein-engineering+2
Sestina BioBerkeley, California, USA2020
synthetic-biologyindustrial-biotech+3
Stipple BioBoston, Massachusetts, USA2021
single-celltarget-discovery+3
10x GenomicsPleasanton, California, USA2012
genomics-sequencingbiotech+1
Ginkgo BioworksBoston, Massachusetts, USA2008
synthetic-biologybiotech+3
Twist BioscienceSouth San Francisco, California, USA2013
genomics-sequencingbiotech+3
Xeris BiopharmaChicago, Illinois, USA2005
biopharmaceuticalsdrug-delivery+3
Freya BiosciencesSouth San Francisco, California, USA2019
therapeuticsbiotech+2